Home / Patient Care / COVID-19 Monoclonal Antibody Therapies - Patients
COVID-19 Monoclonal Antibody Therapies
General Information for Patients
Stanford Health Care is providing COVID-19 monoclonal antibody (mAb) therapies to eligible patients, whether within or outside of the Stanford Health Care system, in accordance with the Food & Drug Administration (FDA) Emergency Use Authorization (EUA) criteria.
Monoclonal antibodies are a specific type of therapy being used to treat COVID-19. Depending on age, health history, and duration of COVID-19 symptoms, you may qualify for a treatment for the infection. To learn more about what these therapies are and how they can prevent mild to moderate symptoms from getting worse, please visit combatCOVID.hhs.gov and talk to your doctor.
Request to be screened for treatment:
Locations
Hoover Medical Pavilion
Infusion Center
211 Quarry Road, 2nd Floor
Palo Alto, CA 94304
General Information for Patients
Stanford Health Care is providing COVID-19 monoclonal antibody (mAb) therapies to eligible patients, whether within or outside of the Stanford Health Care system, in accordance with the Food & Drug Administration (FDA) Emergency Use Authorization (EUA) criteria.
Monoclonal antibodies are a specific type of therapy being used to treat COVID-19. Depending on age, health history, and duration of COVID-19 symptoms, you may qualify for a treatment for the infection. To learn more about what these therapies are and how they can prevent mild to moderate symptoms from getting worse, please visit combatCOVID.hhs.gov and talk to your doctor.
Request to be screened for treatment:
Locations
Hoover Medical Pavilion
Infusion Center
211 Quarry Road, 2nd Floor
Palo Alto, CA 94304
Eligibility Requirements
Criteria:
In order to qualify to receive this treatment, you must test positive for COVID-19 and be less than 10 days from onset of symptoms, plus meet one of the criteria below:
- Over 65 years old
- Over 55 years old with comorbidities such as cardiovascular disease, high blood pressure, or COPD/other chronic respiratory disease
- Over 18 years old with comorbidities such as diabetes, immunosuppressive disease, chronic kidney disease, or obesity (elevated BMI)
Who is not eligible for this treatment?
Individuals would not be eligible for this treatment if they are:
- Hospitalized for COVID-19
- Requiring oxygen therapy due to COVID-19
- Requiring an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
- Allergic to any of the ingredients in the medication
Scheduling Process
Please submit a self-referral form using the link below to be screened for the monoclonal antibody (mAb) treatment. A team member will review your response and contact you via phone or email within 24 hours to request additional information, if necessary, and to discuss appropriateness of infusion.
Instructions for Appointment
This is a one-dose therapy. Your time at the treatment center will be approximately three hours in total. You will have an intravenous line (IV) started in your arm, the infusion will take one hour, and then you will be observed by the nurse for one additional hour. While in the treatment center, you must keep your mask on the entire time and not have anything to eat or drink. Bathroom facilities are available. You will receive a voucher for parking fees.
If you have questions, please send an email to dl-shc-pharmacy-covid@stanfordhealthcare.org. A member of the Monoclonal Antibody Infusion Center team will respond to your email.
Are you a health care provider?
Physicians and healthcare providers — Learn More »
Frequently Asked Questions
There are several monoclonal antibody treatments available to treat COVID-19. Your doctors will select the therapy that is available and most effective against the COVID-19 virus. You will be given more detailed information about the specific medication at the time that you receive treatment.
Tell your health care provider about all of your medical conditions, including if you:
- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescription, over-the-counter, vitamins, and herbal products)
- Monoclonal antibody treatment is given to you through a vein (intravenous or IV).
- You will receive one dose of monoclonal antibody treatment by IV infusion. The infusion will take 16-60 minutes or longer. Your health care provider will determine the duration of your infusion.
As with any treatment, there is the potential to experience side effects. The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
To learn more about potential side effects of the monoclonal antibody therapy talk to your doctor or visit the Health and Human Services website.
Like monoclonal antibody treatment, the FDA may allow for the emergency use of other medicines to treat people with COVID-19. Go to covid19treatmentguidelines.nih.gov for information on the emergency use of other medicines that are not approved by the FDA to treat people with COVID-19. Your health care provider may talk with you about clinical trials you may be eligible for. It is your choice to be treated or not to be treated with monoclonal antibodies. Should you decide not to receive monoclonal antibody treatment or stop it at any time, it will not change your standard medical care.
There is limited experience treating pregnant women or breastfeeding mothers with monoclonal antibodies. For a mother and unborn baby, the benefit of receiving monoclonal antibody treatment may be greater than the risk from the treatment. If you are pregnant or breastfeeding, discuss your options and specific situation with your health care provider.
Tell your health care provider right away if you have any side effect that bothers you or does not go away. Report side effects to FDA MedWatch at fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
- Ask your health care provider.
- Visit Health and Human Services.
- Contact your local or state public health department.
The United States FDA has made monoclonal antibody treatment available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services' (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.
Monoclonal antibody treatment has not undergone the same type of review as an FDA approved or cleared product. The FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that it is reasonable to believe that the product meets certain criteria for safety, performance, and labeling and may be effective in treatment of patients during the COVID-19 pandemic. All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic.
The EUA for monoclonal antibody treatment is in effect for the duration of the COVID-19 declaration justifying emergency use of these products, unless terminated or revoked (after which the product may no longer be used).